Clinical Research

Clinical Research

The research priorities in the area of existing opportunities for PharmaCept GmbH lie in the field of loco-regional tumour therapy / chemoembolisation of liver and lung tumours. In addition to researching important therapy-related questions within the context of embolisation, our continuous interest includes specific studies on the effectiveness and improvement of our products that are already on the market, particularly compounds and instructions relating to prostate and bladder cancer treatment.

In cooperation with universities and other research facilities we initiate and support, among others, the following research areas:

  • Chemoembolisation of tumours and their combination with other loco-regional tumour therapy realization
  • Chemo-instillation of superficial bladder tumours
  • Chemotherapy of castration-resistant prostate cancer

As one of the first results of study projects supported by us, for the first time we were able to present a unique, nationwide data collection (Lingnau et al.), which transformed some of the obvious discrepancies in the area of superficial bladder cancer treatment into the up-to-date international guidelines. Now our ambition, along with pure data collection, is to help solve the remaining therapy problems. The discussion about these results here may be just the beginning. Many medical specialists therefore support the continuation of these studies.

Additionally, last year we succeeded in initiating a first research project, together with the Association for Quality of the Uro-oncologists’ Work Assurance (IQUO). It concerns clinical examination of the current value of estramustine in the treatment of castration resistant prostate cancer.